Loading stock data…
Atara Biotherapeutics, Inc. (ATRA)
$10.51+0.29 (+2.84%)
Market ClosedLast close Jun 26
Atara Biotherapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Atara Biotherapeutics, Inc. in the Healthcare sector is trading at $10.91 with a market capitalization of $87M. Wall Street consensus targets $13.67 (3 analysts), implying a +25.3% move over the next 12 months. The stock is currently 43% below its 52-week high of $19.14, remaining 9.6% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +25.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $516,000↓ | $1.59M↓ | $3.45M↓ | $17.57M↓ | $98.15M |
| Gross Profit | $392,000↓ | $1.49M↓ | $3.34M↓ | $17.02M↓ | $77.71M |
| Operating Income | -$3.37M↓ | -$2.56M↑ | -$3.57M↓ | $3.78M↓ | $38.80M |
| Net Income | -$4.14M↓ | -$3.41M↑ | -$4.30M↓ | $2.39M↓ | $38.01M |
Peer Comparison
JNJUNHPFE
Fundamentals
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy pro...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$86.77M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
25.37%
Volume
Today's trading volume
45,295
Recent News
Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An End
Biotech stocks climbed Wednesday after the Food and Drug Administration signaled the end of a "nail-biting journey" for UniQure.
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know
Atara stock soars 82% as the FDA outlines a regulatory pathway for its lead product candidate, tab-cel, reviving hopes for potential U.S. approval, after two prior CRLs.
FDA Resubmission Path for Tab-cel Keeps Atara’s (ATRA) Regulatory Timeline Alive
Atara Biotherapeutics said the FDA outlined a potential pathway for resubmitting the tabelecleucel application after a recent Complete Response Letter. Key Investor TakeawaysAtara Biotherapeutics (NASDAQ:ATRA) said the FDA discussed a potential resubmission path for tabelecleucel following a Type A meeting.
Atara Biotherapeutics, Inc. (ATRA) Registers Possible Resale of 400K Common Shares Tied to HCR Warrant Exercise
We recently compiled a list of the 10 Best Cheap Stocks Under $10 to Buy in April. Atara Biotherapeutics, Inc. is among the best cheap stocks to buy. TheFly reported on March 17 that ATRA filed a prospectus to register the potential resale of up to 400,000 common shares by HCR Molag Fund, L.P. These […]
Atara Biotherapeutics: Q4 Earnings Snapshot
ATRA) on Monday reported a loss of $3.4 million in its fourth quarter. The Thousand Oaks, California-based company said it had a loss of 25 cents per share. The drug developer posted revenue of $1.6 million in the period.